Merck
@Merck
We aspire to be the premier research-intensive biopharmaceutical company. Intended for U.S. residents only. FLS: http://merck.us/3TKXNuZ
In collaboration with @GatesFoundation, we are excited to share the latest updates in our work to develop a potential new #HIV prevention option. Learn more: merck.us/3GG9ajF
Today we announced an agreement to acquire Verona Pharma. Through this acquisition, we will add a novel, important maintenance treatment for chronic obstructive pulmonary disease (#COPD) to strengthen & complement our diversified cardio-pulmonary portfolio merck.us/4ldkym5
We’re excited to share our latest #HIV updates, which will be presented at IAS 2025. Learn more: merck.us/45ZzCiq
We’re pleased to announce the #FDA has granted priority review to our application related to pulmonary arterial hypertension (#PAH). Learn more here: merck.us/4lxdtfI
We’re pleased to announce topline results from our latest Phase 3 study in pulmonary arterial hypertension (#PAH). Learn more here: merck.us/4nadSql
Today, we announced the initiation of a Phase 3 trial in metastatic castration-resistant #prostatecancer, in collaboration with @DaiichiSankyoUS. Learn more: merck.us/4ebH1NR
Today’s #FDA approval marks a significant step forward for certain patients with head and neck squamous cell carcinoma. Learn more here: merck.us/4e7cEYS
Today, we announced the initiation of our Phase 3 clinical study in #dengue. Learn more: merck.us/45RZnRD
We’re proud to announce the #FDA approval of a new option to help protect infants against respiratory syncytial virus (#RSV). Learn more: merck.us/3HzfCce
We’re excited to share recent data from our Phase 3 clinical trials in #cardiovascular disease as we continue to work toward new treatment options for adults with hyperlipidemia. Read more: merck.us/43QN59p
In collaboration with @GileadSciences, we’re presenting new data from this Phase 3 study in triple-negative breast cancer (#TNBC) that builds on existing evidence and offers additional insights. Learn more in the official #ASCO25 Press Program: merck.us/45ydVWj
Today, we shared new, early data for one of our investigational candidates for non-small cell #lungcancer and #colorectalcancer at #ASCO25. Learn more here: merck.us/4jpKSre
Today at #ASCO25, we continue to advance our oncology pipeline with the presentation of new data from a Phase 2/3 study of our investigational #hematology candidate in diffuse large B-cell lymphoma. Learn more here: merck.us/43p0zdS
Our 2025 Annual Meeting of Shareholders will be held virtually on May 27. Tune in via webcast to hear about our company’s impact over the past year, and our ongoing efforts to accelerate and advance our broad and innovative pipeline. Learn more: merck.us/3tlVbFE
Today, we announced the initiation of a Phase 3 trial in unresectable advanced or metastatic #esophageal squamous cell carcinoma, in collaboration with @DaiichiSankyoUS. Learn more: merck.us/43B3HTJ
We're looking forward to sharing new data from our Pulmonary Arterial Hypertension (#PAH) clinical program at #ATS2025. Learn more: merck.us/43xXqIs
Today, we announced new Phase 3 topline results for our #immunotherapy in platinum-resistant recurrent #ovariancancer. Learn more about our results here: merck.us/4jYtGdK
We’re pleased to highlight new research spanning more than 25 types of #cancer at @ASCO this year. Learn more about the novel approaches we’re exploring across our broad and differentiated #oncology portfolio: merck.us/4iX5Ai3 #ASCO25
Today’s #FDA approval provides a new option for certain patients with pheochromocytoma or paraganglioma (#PPGL). Learn more here: merck.us/3ZglGMK